<DOC>
	<DOCNO>NCT00481676</DOCNO>
	<brief_summary>This study evaluate safety efficacy omalizumab adult patient moderate severe chronic urticaria exhibit IgE thyroperoxidase .</brief_summary>
	<brief_title>Efficacy Safety Omalizumab Adults ( 18-70 Years ) With Moderate Severe Chronic Urticaria</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Clemastine</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Males females 1870 year age Body weight ≥ 20 kg ≤ 150 kg total serum IgE level ≥ 30 IU/mL ≤ 700 IU/mL Specific serum IgE antiTPO level ≥ 8.0 IU/mL , document within 3 month prior randomization time prescreening Diagnosis moderate severe chronic urticaria Subject 's current episode chronic urticaria accord European Academy Allergology Clinical Immunology/Global Allergy Asthma European Network/European Dermatology Forum ( EAACI/GA2LEN/EDF ) guideline time screen Current episode chronic urticaria respond approve market dose antihistamine 2 week longer Urticaria activity score ( UAS ) ≥ 0 7 day first section screen period UAS7 ≥ 10 time randomization Exclusion criterion : Females childbearing potential breast feeding Present past medical condition could interfere study result Randomized omalizumab study receive omalizumab Received investigational drug within 30 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Chronic urticaria , omalizumab , thyroperoxidase , IgE</keyword>
</DOC>